GefitinibDiarrhoea and acquired drug resistance: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1731卷 / 1期

关键词：

D O I：

10.1007/s40278-018-55319-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：124 / 124

相关论文

共 50 条

[31] Immunosuppressants/entecavirHepatitis B reactivation and acquired drug resistance: case report
Reactions Weekly, 2022, 1902 (1) : 244 - 244
[32] PonatinibOff-label use followed by acquired drug resistance: case report
Reactions Weekly, 2021, 1885 (1) : 446 - 446
[33] AfatinibTransformation to small cell lung cancer and acquired drug resistance: case report
Reactions Weekly, 2018, 1696 (1) : 17 - 17
[34] Multiple drugsVarious toxicities, acquired drug resistance and therapy failure: case report
Reactions Weekly, 2023, 1948 (1) : 327 - 327
[35] Adalimumab/azathioprine/ustekinumabAnaphylaxis, genital rash and acquired drug resistance: case report
Reactions Weekly, 2024, 2025 (1) : 23 - 23
[36] Cotrimoxazole/Minocycline/TigecyclineLack of efficacy, acquired drug resistance and emesis: case report
Reactions Weekly, 2025, 2043 (1) : 118 - 118
[37] Amphotericin-B/MicafunginLack of efficacy and acquired drug resistance: case report
Reactions Weekly, 2025, 2051 (1) : 30 - 30
[38] Lenvatinib/regorafenib/sorafenibTreatment failure, acquired drug resistance and proteinuria: case report
Reactions Weekly, 2021, 1854 (1) : 206 - 206
[39] Epirubicin/lapatinib/trastuzumabImpaired liver function and acquired drug resistance: case report
Reactions Weekly, 2021, 1850 (1) : 129 - 129
[40] Multiple drugsVarious toxicities, acquired drug resistance and lack of efficacy: case report
Reactions Weekly, 2023, 1968 (1) : 231 - 231

← 1 2 3 4 5 →